| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Fmoc-Asp-Oall is classified as a protected amino acid and does not have a specific biological receptor target. Its primary application is as a building block for introducing aspartic acid residues with C-terminal allyl ester protection during Fmoc-based SPPS. The allyl ester provides orthogonal C-terminal protection that can be selectively removed by palladium catalysis.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
In vitro activity for Fmoc-Asp-Oall is primarily as a peptide synthesis reagent. Amino acid derivatives have been commercially studied as ergogenic supplements, influencing the secretion of anabolic hormones, fuel availability, mental performance, and prevention of exercise-induced muscle damage. Fmoc-Asp-Oall itself is not directly biologically active; its utility is in preparing aspartic acid-containing peptides for subsequent evaluation. |
| ln Vivo |
In vivo activity data for Fmoc-Asp-Oall as a standalone compound is not applicable. It is a protected amino acid building block used in research and is not intended for direct in vivo administration. Peptides synthesized using this building block may be evaluated in animal models for various biological activities. The protecting groups are typically removed before biological testing.
|
| Enzyme Assay |
In vitro SPPS protocols for Fmoc-Asp-Oall involve standard Fmoc chemistry. The compound is activated with coupling reagents such as HATU or HBTU and DIPEA in DMF, then coupled to resin-bound peptides. Fmoc deprotection uses 20% piperidine in DMF. The allyl ester is removed by palladium-catalyzed deallylation. Purity is typically ≥97% by HPLC.
|
| Cell Assay |
Cell-based protocols are not directly applicable to Fmoc-Asp-Oall as it is a protected amino acid derivative. Aspartic acid-containing peptides synthesized using this reagent can be tested in cell culture after deprotection. Peptides are dissolved in DMSO or appropriate buffers and added to cells at concentrations of 0.1-100 µM for 24-72 hours.
|
| Animal Protocol |
Animal studies with Fmoc-Asp-Oall are not conducted directly. Peptides containing aspartic acid residues synthesized using this building block may be evaluated in vivo. Protocols involve administration of the peptide via appropriate routes in animal models. Pharmacokinetic sampling, efficacy assessment, and toxicological evaluation follow standard preclinical study designs.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Fmoc-Asp-Oall as a standalone compound is not applicable. The compound has a molecular weight of 395.41 g/mol, formula C22H21NO6, and melting point of 131.0 to 135.0°C. Storage is recommended at 2-8°C. The Fmoc group is removed under basic conditions during peptide synthesis.
|
| Toxicity/Toxicokinetics |
Limited toxicological data is available for Fmoc-Asp-Oall. The compound is for research use only and is not intended for human therapeutic use. Standard safety precautions for handling protected amino acids should be observed. No specific toxicity studies have been reported.
|
| References | |
| Additional Infomation |
Fmoc-Asp-Oall (CAS#: 144120-53-6) is also known as N-Fmoc-L-aspartic acid α-allyl ester, 1-Allyl N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-L-aspartate, and (3S)-3-(9H-fluoren-9-ylmethoxycarbonylamino)-4-oxo-4-prop-2-enoxybutanoic acid. It is an aspartic acid analogue. It has no approved therapeutic indications.
|
| Molecular Formula |
C22H21NO6
|
|---|---|
| Molecular Weight |
395.40524
|
| Exact Mass |
395.136
|
| CAS # |
144120-53-6
|
| PubChem CID |
7020604
|
| Appearance |
White to off-white powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
638.5±55.0 °C at 760 mmHg
|
| Melting Point |
-95ºC (dec.)
|
| Flash Point |
340.0±31.5 °C
|
| Vapour Pressure |
0.0±2.0 mmHg at 25°C
|
| Index of Refraction |
1.592
|
| LogP |
4.75
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
29
|
| Complexity |
598
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O=C(O)C[C@H](NC(OCC1C2=C(C3=C1C=CC=C3)C=CC=C2)=O)C(OCC=C)=O
|
| InChi Key |
ZJMVIWUCCRKNHY-IBGZPJMESA-N
|
| InChi Code |
InChI=1S/C22H21NO6/c1-2-11-28-21(26)19(12-20(24)25)23-22(27)29-13-18-16-9-5-3-7-14(16)15-8-4-6-10-17(15)18/h2-10,18-19H,1,11-13H2,(H,23,27)(H,24,25)/t19-/m0/s1
|
| Chemical Name |
(3S)-3-(9H-fluoren-9-ylmethoxycarbonylamino)-4-oxo-4-prop-2-enoxybutanoic acid
|
| Synonyms |
(S)-3-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-4-(allyloxy)-4-oxobutanoic acid; Fmoc-Asp-Oall
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~252.90 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.43 mg/mL (3.62 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 14.3 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.43 mg/mL (3.62 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 14.3 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.43 mg/mL (3.62 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5290 mL | 12.6451 mL | 25.2902 mL | |
| 5 mM | 0.5058 mL | 2.5290 mL | 5.0580 mL | |
| 10 mM | 0.2529 mL | 1.2645 mL | 2.5290 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
